Search

Your search keyword '"Poniman, Meliawati"' showing total 46 results
Start Over Author "Poniman, Meliawati"
46 results on '"Poniman, Meliawati"'

2. Broad SARS-CoV-2 neutralization by monoclonal and bispecific antibodies derived from a Gamma-infected individual

Author

Guerra, Denise, Beaumont, Tim, Radić, Laura, Kerster, Gius, van der Straten, Karlijn, Yuan, Meng, Torres, Jonathan L., Lee, Wen-Hsin, Liu, Hejun, Poniman, Meliawati, Bontjer, Ilja, Burger, Judith A., Claireaux, Mathieu, Caniels, Tom G., Snitselaar, Jonne L., Bijl, Tom P.L., Kruijer, Sabine, Ozorowski, Gabriel, Gideonse, David, Sliepen, Kwinten, Ward, Andrew B., Eggink, Dirk, de Bree, Godelieve J., Wilson, Ian A., Sanders, Rogier W., and van Gils, Marit J.

Published
2023
Full Text
View/download PDF

3. Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study

Author

Kant, Iris M.J., Graas, Thecla, Toussaint, Belle, de Jong, Sterre, Darwesh, Shahan, Mahes, Sandjiv S., Kamminga, Dora, Koelewijn, Matthijs, Faber, Gino, Beaumont, Guus, Engel, Marije D., Pierie, R. Cheyenne N., Janssen, Suzanne R., van Dijkman, Edith, Heijmans, Jarom, Witte, Yara Y., Nahui Palomino, Rogers A., Omar, Said Z., Zweegman, Sonja, Kater, Arnon P., van den Vegt, Caya, Arends-Halbesma, Ilonka, de Pater, Emma, Dijkstra, Margriet J., Rots, Nynke Y., Rijnstra, Esther Siteur-van, de Rooij, Dennis M., Sanders, Rogier W., Poniman, Meliawati, Olijhoek, Wouter, van Rijswijk, Jacqueline, Beaumont, Tim, Çetinel, Lusia, Schellekens, Louis, den Hartogh, Yvonne M., Cloos, Jacqueline, Weijers, Suzanne S., Tonouh-Aajoud, Saïda, Avci, Selime, Roelandse-Koop, Elianne, Dik, Willem A., Hofsink, Quincy, Haggenburg, Sabine, Lissenberg-Witte, Birgit I., Broers, Annoek E.C., van Doesum, Jaap A., van Binnendijk, Rob S., den Hartog, Gerco, Bhoekhan, Michel S., Haverkate, Nienke J.E., van Meerloo, Johan, Burger, Judith A., Bouhuijs, Joey H., Smits, Gaby P., Wouters, Dorine, van Leeuwen, Ester M.M., Bontkes, Hetty J., Kootstra, Neeltje A., Vogels-Nooijen, Sandra, Rots, Nynke, van Beek, Josine, Heemskerk, Mirjam H.M., Groen, Kazimierz, van Meerten, Tom, Mutsaers, Pim G.N.J., van Gils, Marit J., Goorhuis, Abraham, Rutten, Caroline E., Hazenberg, Mette D., and Nijhof, Inger S.

Published
2023
Full Text
View/download PDF

4. Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses

Author

Radić, Laura, Sliepen, Kwinten, Yin, Victor, Brinkkemper, Mitch, Capella-Pujol, Joan, Schriek, Angela I., Torres, Jonathan L., Bangaru, Sandhya, Burger, Judith A., Poniman, Meliawati, Bontjer, Ilja, Bouhuijs, Joey H., Gideonse, David, Eggink, Dirk, Ward, Andrew B., Heck, Albert J.R., Van Gils, Marit J., Sanders, Rogier W., and Schinkel, Janke

Published
2023
Full Text
View/download PDF

5. Broadening sarbecovirus neutralization with bispecific antibodies combining distinct conserved targets on the receptor binding domain

Author

Guerra, Denise, primary, Radić, Laura, additional, Brinkkemper, Mitch, additional, Poniman, Meliawati, additional, van der Maas, Lara, additional, Torres, Jonathan L., additional, Ward, Andrew B., additional, Sliepen, Kwinten, additional, Schinkel, Janke, additional, Sanders, Rogier W., additional, van Gils, Marit J., additional, and Beaumont, Tim, additional

Published
2024
Full Text
View/download PDF

6. Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses

Author

Brinkkemper, Mitch, Veth, Tim S., Brouwer, Philip J.M., Turner, Hannah, Poniman, Meliawati, Burger, Judith A., Bouhuijs, Joey H., Olijhoek, Wouter, Bontjer, Ilja, Snitselaar, Jonne L., Caniels, Tom G., van der Linden, Cynthia A., Ravichandran, Rashmi, Villaudy, Julien, van der Velden, Yme U., Sliepen, Kwinten, van Gils, Marit J., Ward, Andrew B., King, Neil P., Heck, Albert J.R., and Sanders, Rogier W.

Published
2022
Full Text
View/download PDF

7. Recent infection with HCoV-OC43 may be associated with protection against SARS-CoV-2 infection

Author

Lavell, A.H. Ayesha, Sikkens, Jonne J., Edridge, Arthur W.D., van der Straten, Karlijn, Sechan, Ferdyansyah, Oomen, Melissa, Buis, David T.P., Schinkel, Michiel, Burger, Judith A., Poniman, Meliawati, van Rijswijk, Jacqueline, de Jong, Menno D., de Bree, Godelieve J., Peters, Edgar J.G., Smulders, Yvo M., Sanders, Rogier W., van Gils, Marit J., van der Hoek, Lia, and Bomers, Marije K.

Published
2022
Full Text
View/download PDF

9. A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike

Author

Claireaux, Mathieu, Caniels, Tom G., de Gast, Marlon, Han, Julianna, Guerra, Denise, Kerster, Gius, van Schaik, Barbera D. C., Jongejan, Aldo, Schriek, Angela I., Grobben, Marloes, Brouwer, Philip J. M., van der Straten, Karlijn, Aldon, Yoann, Capella-Pujol, Joan, Snitselaar, Jonne L., Olijhoek, Wouter, Aartse, Aafke, Brinkkemper, Mitch, Bontjer, Ilja, Burger, Judith A., Poniman, Meliawati, Bijl, Tom P. L., Torres, Jonathan L., Copps, Jeffrey, Martin, Isabel Cuella, de Taeye, Steven W., de Bree, Godelieve J., Ward, Andrew B., Sliepen, Kwinten, van Kampen, Antoine H. C., Moerland, Perry D., Sanders, Rogier W., and van Gils, Marit J.

Published
2022
Full Text
View/download PDF

11. Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients

Author

Haggenburg, Sabine, Lissenberg-Witte, Birgit I., van Binnendijk, Rob S., den Hartog, Gerco, Bhoekhan, Michel S., Haverkate, Nienke J.E., de Rooij, Dennis M., van Meerloo, Johan, Cloos, Jacqueline, Kootstra, Neeltje A., Wouters, Dorine, Weijers, Suzanne S., van Leeuwen, Ester M.M., Bontkes, Hetty J., Tonouh-Aajoud, Saïda, Heemskerk, Mirjam H.M., Sanders, Rogier W., Roelandse-Koop, Elianne, Hofsink, Quincy, Groen, Kazimierz, Çetinel, Lucia, Schellekens, Louis, den Hartog, Yvonne M., Toussaint, Belle, Kant, Iris M.J., Graas, Thecla, de Pater, Emma, Dik, Willem A., Engel, Marije D., Pierie, Cheyenne R.N., Janssen, Suzanne R., van Dijkman, Edith, Poniman, Meliawati, Burger, Judith A., Bouhuijs, Joey H., Smits, Gaby, Rots, Nynke Y., Zweegman, Sonja, Kater, Arnon P., van Meerten, Tom, Mutsaers, Pim G.N.J., van Doesum, Jaap A., Broers, Annoek E.C., van Gils, Marit J., Goorhuis, Abraham, Rutten, Caroline E., Hazenberg, Mette D., and Nijhof, Inger S.

Published
2022
Full Text
View/download PDF

12. Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection

Author

Sulbaran, Guidenn, Maisonnasse, Pauline, Amen, Axelle, Effantin, Gregory, Guilligay, Delphine, Dereuddre-Bosquet, Nathalie, Burger, Judith A., Poniman, Meliawati, Grobben, Marloes, Buisson, Marlyse, Dergan Dylon, Sebastian, Naninck, Thibaut, Lemaître, Julien, Gros, Wesley, Gallouët, Anne-Sophie, Marlin, Romain, Bouillier, Camille, Contreras, Vanessa, Relouzat, Francis, Fenel, Daphna, Thepaut, Michel, Bally, Isabelle, Thielens, Nicole, Fieschi, Franck, Schoehn, Guy, van der Werf, Sylvie, van Gils, Marit J., Sanders, Rogier W., Poignard, Pascal, Le Grand, Roger, and Weissenhorn, Winfried

Published
2022
Full Text
View/download PDF

13. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern

Author

Agard, Ivette, Ayal, Jane, Boyd, Anders, Cavdar, Floor, Craanen, Marianne, Davidovich, Udi, Deuring, Annemarieke, van Dijk, Annelies, Ersan, Ertan, del Grande, Laura, Hartman, Joost, Koedoot, Nelleke, Leenstra, Tjalling, Loomans, Dominique, Makowska, Agata, du Maine, Tom, de Man, Ilja, Matser, Amy, van der Meij, Lizenka, van Polanen, Marleen, Oud, Maria, Reid, Clark, Storey, Leeann, de Wit, Marije, van Wijk, Marc, van Assem, Joyce, van den Aardweg, Joost, van Beek, Marijne, Blankert, Thyra, Boeser-Nunnink, Brigitte, Moll van Charante, Eric, van Dort, Karel, Figaroa, Orlane, Frenkel, Leah, Girigorie, Arginell, van Haga, Jelle, Harskamp-Holwerda, Agnes, Hazenberg, Mette, Hidad, Soemeja, de Jong, Nina, Jonges, Marcel, Jurriaans, Suzanne, Knoop, Hans, Kuijt, Lara, Lok, Anja, Ruiz, Marga Mangas, Maurer, Irma, Nieuwkerk, Pythia, van Nuenen, Ad, van der Veen, Annelou, Verkaik, Bas, Visser, Gerben-Rienk, van Gils, Marit J., van Willigen, Hugo D.G., Wynberg, Elke, Han, Alvin X., van der Straten, Karlijn, Burger, Judith A., Poniman, Meliawati, Oomen, Melissa, Tejjani, Khadija, Bouhuijs, Joey H., Verveen, Anouk, Lebbink, Romy, Dijkstra, Maartje, Appelman, Brent, Lavell, A.H. Ayesha, Caniels, Tom G., Bontjer, Ilja, van Vught, Lonneke A., Vlaar, Alexander P.J., Sikkens, Jonne J., Bomers, Marije K., Russell, Colin A., Kootstra, Neeltje A., Sanders, Rogier W., Prins, Maria, de Bree, Godelieve J., and de Jong, Menno D.

Published
2022
Full Text
View/download PDF

14. COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models

Author

Maisonnasse, Pauline, Aldon, Yoann, Marc, Aurélien, Marlin, Romain, Dereuddre-Bosquet, Nathalie, Kuzmina, Natalia A., Freyn, Alec W., Snitselaar, Jonne L., Gonçalves, Antonio, Caniels, Tom G., Burger, Judith A., Poniman, Meliawati, Bontjer, Ilja, Chesnais, Virginie, Diry, Ségolène, Iershov, Anton, Ronk, Adam J., Jangra, Sonia, Rathnasinghe, Raveen, Brouwer, Philip J. M., Bijl, Tom P. L., van Schooten, Jelle, Brinkkemper, Mitch, Liu, Hejun, Yuan, Meng, Mire, Chad E., van Breemen, Mariëlle J., Contreras, Vanessa, Naninck, Thibaut, Lemaître, Julien, Kahlaoui, Nidhal, Relouzat, Francis, Chapon, Catherine, Ho Tsong Fang, Raphaël, McDanal, Charlene, Osei-Twum, Mary, St-Amant, Natalie, Gagnon, Luc, Montefiori, David C., Wilson, Ian A., Ginoux, Eric, de Bree, Godelieve J., García-Sastre, Adolfo, Schotsaert, Michael, Coughlan, Lynda, Bukreyev, Alexander, van der Werf, Sylvie, Guedj, Jérémie, Sanders, Rogier W., van Gils, Marit J., and Le Grand, Roger

Published
2021
Full Text
View/download PDF

16. Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study

Author

van Gils, Marit J., Lavell, Ayesha, van der Straten, Karlijn, Appelman, Brent, Bontjer, Ilja, Poniman, Meliawati, Burger, Judith A., Oomen, Melissa, Bouhuijs, Joey H., van Vught, Lonneke A., Slim, Marleen A., Schinkel, Michiel, Wynberg, Elke, van Willigen, Hugo D. G., Grobben, Marloes, Tejjani, Khadija, van Rijswijk, Jacqueline, Snitselaar, Jonne L., Caniels, Tom G., Vlaar, Alexander P. J., Prins, Maria, de Jong, Menno D., de Bree, Godelieve J., Sikkens, Jonne J., Bomers, Marije K., and Sanders, Rogier W.

Subjects
Viral antibodies -- Evaluation -- Comparative analysis, Antibodies -- Evaluation -- Comparative analysis, Medical personnel -- Health aspects, Biological sciences
Abstract

Background Emerging and future SARS-CoV-2 variants may jeopardize the effectiveness of vaccination campaigns. Therefore, it is important to know how the different vaccines perform against diverse SARS-CoV-2 variants. Methods and findings In a prospective cohort of 165 SARS-CoV-2 naive health care workers in the Netherlands, vaccinated with either one of four vaccines (BNT162b2, mRNA-1273, AZD1222 or Ad26.COV2.S), we performed a head-to-head comparison of the ability of sera to recognize and neutralize SARS-CoV-2 variants of concern (VOCs; Alpha, Beta, Gamma, Delta and Omicron). Repeated serum sampling was performed 5 times during a year (from January 2021 till January 2022), including before and after booster vaccination with BNT162b2. Four weeks after completing the initial vaccination series, SARS-CoV-2 wild-type neutralizing antibody titers were highest in recipients of mRNA-1273, followed by recipients of BNT162b2 (geometric mean titers (GMT) of 358 [95% CI 231-556] and 214 [95% CI 153-299], respectively; p Conclusions Overall, this study shows that the mRNA vaccines appear superior to adenovirus vector-based vaccines in inducing neutralizing antibodies against VOCs four weeks after initial vaccination and after booster vaccination, which implies the use of mRNA vaccines for both initial and booster vaccination., Author(s): Marit J. van Gils 1,*, Ayesha Lavell 2, Karlijn van der Straten 1,3, Brent Appelman 4, Ilja Bontjer 1, Meliawati Poniman 1, Judith A. Burger 1, Melissa Oomen 1, [...]

Published
2022
Full Text
View/download PDF

19. Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study

Author

Hofsink, Quincy, primary, Haggenburg, Sabine, additional, Lissenberg-Witte, Birgit I., additional, Broers, Annoek E.C., additional, van Doesum, Jaap A., additional, van Binnendijk, Rob S., additional, den Hartog, Gerco, additional, Bhoekhan, Michel S., additional, Haverkate, Nienke J.E., additional, van Meerloo, Johan, additional, Burger, Judith A., additional, Bouhuijs, Joey H., additional, Smits, Gaby P., additional, Wouters, Dorine, additional, van Leeuwen, Ester M.M., additional, Bontkes, Hetty J., additional, Kootstra, Neeltje A., additional, Vogels-Nooijen, Sandra, additional, Rots, Nynke, additional, van Beek, Josine, additional, Heemskerk, Mirjam H.M., additional, Groen, Kazimierz, additional, van Meerten, Tom, additional, Mutsaers, Pim G.N.J., additional, van Gils, Marit J., additional, Goorhuis, Abraham, additional, Rutten, Caroline E., additional, Hazenberg, Mette D., additional, Nijhof, Inger S., additional, Kant, Iris M.J., additional, Graas, Thecla, additional, Toussaint, Belle, additional, de Jong, Sterre, additional, Darwesh, Shahan, additional, Mahes, Sandjiv S., additional, Kamminga, Dora, additional, Koelewijn, Matthijs, additional, Faber, Gino, additional, Beaumont, Guus, additional, Engel, Marije D., additional, Pierie, R. Cheyenne N., additional, Janssen, Suzanne R., additional, van Dijkman, Edith, additional, Heijmans, Jarom, additional, Witte, Yara Y., additional, Nahui Palomino, Rogers A., additional, Omar, Said Z., additional, Zweegman, Sonja, additional, Kater, Arnon P., additional, van den Vegt, Caya, additional, Arends-Halbesma, Ilonka, additional, de Pater, Emma, additional, Dijkstra, Margriet J., additional, Rots, Nynke Y., additional, Rijnstra, Esther Siteur-van, additional, de Rooij, Dennis M., additional, Sanders, Rogier W., additional, Poniman, Meliawati, additional, Olijhoek, Wouter, additional, van Rijswijk, Jacqueline, additional, Beaumont, Tim, additional, Çetinel, Lusia, additional, Schellekens, Louis, additional, den Hartogh, Yvonne M., additional, Cloos, Jacqueline, additional, Weijers, Suzanne S., additional, Tonouh-Aajoud, Saïda, additional, Avci, Selime, additional, Roelandse-Koop, Elianne, additional, and Dik, Willem A., additional

Published
2023
Full Text
View/download PDF

20. Corrigendum: Anti-HIV-1 nanobody-IgG1 constructs with improved neutralization potency and the ability to mediate Fc effector functions

Author

Schriek, Angela I., primary, van Haaren, Marlies M., additional, Poniman, Meliawati, additional, Dekkers, Gillian, additional, Bentlage, Arthur E. H., additional, Grobben, Marloes, additional, Vidarsson, Gestur, additional, Sanders, Rogier W., additional, Verrips, Theo, additional, Geijtenbeek, Teunis B. H., additional, Heukers, Raimond, additional, Kootstra, Neeltje A., additional, de Taeye, Steven W., additional, and van Gils, Marit J., additional

Published
2022
Full Text
View/download PDF

21. Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses

Author

Radić, Laura, primary, Sliepen, Kwinten, additional, Yin, Victor, additional, Brinkkemper, Mitch, additional, Capella-Pujol, Joan, additional, Schriek, Angela I., additional, Torres, Jonathan L., additional, Bangaru, Sandhya, additional, Burger, Judith A., additional, Poniman, Meliawati, additional, Bontjer, Ilja, additional, Bouhuijs, Joey H., additional, Gideonse, David, additional, Eggink, Dirk, additional, Ward, Andrew B., additional, Heck, Albert J. R., additional, Van Gils, Marit J., additional, Sanders, Rogier W., additional, and Schinkel, Janke, additional

Published
2022
Full Text
View/download PDF

22. Broad SARS-CoV-2 Neutralization by Monoclonal and Bispecific Antibodies Derived from a Gamma-infected Individual

Author

Guerra, Denise, primary, Beaumont, Tim, additional, Radić, Laura, additional, Kerster, Gius, additional, van der Straten, Karlijn, additional, Yuan, Meng, additional, Torres, Jonathan L., additional, Lee, Wen-Hsin, additional, Liu, Hejun, additional, Poniman, Meliawati, additional, Bontjer, Ilja, additional, Burger, Judith A., additional, Claireaux, Mathieu, additional, Caniels, Tom G., additional, Snitselaar, Jonne L., additional, Bijl, Tom P. L., additional, Kruijer, Sabine, additional, Ozorowski, Gabriel, additional, Gideonse, David, additional, Sliepen, Kwinten, additional, Ward, Andrew B., additional, Eggink, Dirk, additional, de Bree, Godelieve J., additional, Wilson, Ian A., additional, Sanders, Rogier W., additional, and van Gils, Marit J., additional

Published
2022
Full Text
View/download PDF

23. Antigenic cartography using sera from sequence-confirmed SARS-CoV-2 variants of concern infections reveals antigenic divergence of Omicron

Author

van der Straten, Karlijn, primary, Guerra, Denise, additional, van Gils, Marit J., additional, Bontjer, Ilja, additional, Caniels, Tom G., additional, van Willigen, Hugo D.G., additional, Wynberg, Elke, additional, Poniman, Meliawati, additional, Burger, Judith A., additional, Bouhuijs, Joey H., additional, van Rijswijk, Jacqueline, additional, Olijhoek, Wouter, additional, Liesdek, Marinus H., additional, Lavell, A.H. Ayesha, additional, Appelman, Brent, additional, Sikkens, Jonne J., additional, Bomers, Marije K., additional, Han, Alvin X., additional, Nichols, Brooke E., additional, Prins, Maria, additional, Vennema, Harry, additional, Reusken, Chantal, additional, de Jong, Menno D., additional, de Bree, Godelieve J., additional, Russell, Colin A., additional, Eggink, Dirk, additional, and Sanders, Rogier W., additional

Published
2022
Full Text
View/download PDF

24. Anti-HIV-1 Nanobody-IgG1 Constructs With Improved Neutralization Potency and the Ability to Mediate Fc Effector Functions

Author

Schriek, Angela I, van Haaren, Marlies M, Poniman, Meliawati, Dekkers, Gillian, Bentlage, Arthur E H, Grobben, Marloes, Vidarsson, Gestur, Sanders, Rogier W, Verrips, Theo, Geijtenbeek, Teunis B H, Heukers, Raimond, Kootstra, Neeltje A, de Taeye, Steven W, van Gils, Marit J, Afd Biomol.Mass Spect. and Proteomics, Sub Cell Biology, Biomolecular Mass Spectrometry and Proteomics, Afd Biomol.Mass Spect. and Proteomics, Sub Cell Biology, Biomolecular Mass Spectrometry and Proteomics, Experimental Immunology, Graduate School, Medical Microbiology and Infection Prevention, AII - Infectious diseases, Infectious diseases, APH - Aging & Later Life, and Molecular cell biology and Immunology

Subjects
Fc fusion, Fc-mediated effector functions, Immunology, Single-Domain Antibodies, neutralization, HIV Antibodies, Antibodies, Neutralizing/pharmacology, Antibodies, Neutralizing, Antibodies, nanobodies, Immunoglobulin G, HIV Seropositivity, HIV-1, Humans, Immunology and Allergy, Neutralizing/pharmacology, Broadly Neutralizing Antibodies, Single-Domain Antibodies/pharmacology
Abstract

The most effective treatment for HIV-1, antiretroviral therapy, suppresses viral replication and averts the disease from progression. Nonetheless, there is a need for alternative treatments as it requires daily administration with the possibility of side effects and occurrence of drug resistance. Broadly neutralizing antibodies or nanobodies targeting the HIV-1 envelope glycoprotein are explored as alternative treatment, since they mediate viral suppression and contribute to the elimination of virus-infected cells. Besides neutralization potency and breadth, Fc-mediated effector functions of bNAbs also contribute to thein vivoefficacy. In this study multivalent J3, 2E7 and 1F10 anti-HIV-1 broadly neutralizing nanobodies were generated to improve neutralization potency and IgG1 Fc fusion was utilized to gain Fc-mediated effector functions. Bivalent and trivalent nanobodies, coupled using long glycine-serine linkers, showed increased binding to the HIV-1 Env and enhanced neutralization potency compared to the monovalent variant. Fusion of an IgG1 Fc domain to J3 improved neutralization potency compared to the J3-bihead and restored Fc-mediated effector functions such as antibody-dependent cellular phagocytosis and trogocytosis, and natural killer cell activation. Due to their neutralization breadth and potency and their ability to induce effector functions these nanobody-IgG1 constructs may prove to be valuable towards alternative HIV-1 therapies.

Published
2022

25. Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity

Author

van Leeuwen, Leanne P.M., primary, GeurtsvanKessel, Corine H., additional, Ellerbroek, Pauline M., additional, de Bree, Godelieve J., additional, Potjewijd, Judith, additional, Rutgers, Abraham, additional, Jolink, Hetty, additional, van de Veerdonk, Frank, additional, van Gorp, Eric C.M., additional, de Wilt, Faye, additional, Bogers, Susanne, additional, Gommers, Lennert, additional, Geers, Daryl, additional, Bruns, Anke H.W., additional, Leavis, Helen L., additional, van Haga, Jelle W., additional, Lemkes, Bregtje A., additional, van der Veen, Annelou, additional, de Kruijf-Bazen, S.F.J., additional, van Paassen, Pieter, additional, de Leeuw, Karina, additional, van de Ven, Annick A.J.M., additional, Verbeek-Menken, Petra H., additional, van Wengen, Annelies, additional, Arend, Sandra M., additional, Ruten-Budde, Anja J., additional, van der Ent, Marianne W., additional, van Hagen, P. Martin, additional, Sanders, Rogier W., additional, Grobben, Marloes, additional, van der Straten, Karlijn, additional, Burger, Judith A., additional, Poniman, Meliawati, additional, Nierkens, Stefan, additional, van Gils, Marit J., additional, de Vries, Rory D., additional, and Dalm, Virgil A.S.H., additional

Published
2022
Full Text
View/download PDF

26. IgG1 responses following SARS-CoV-2 infection are polyclonal and highly personalized, whereby each donor and each clone displays a distinct pattern of cross-reactivity against SARS-CoV-2 variants

Author

van Rijswijck, Danique M.H., primary, Bondt, Albert, additional, Hoek, Max, additional, van der Straten, Karlijn, additional, Caniels, Tom G, additional, Poniman, Meliawati, additional, Eggink, Dirk, additional, Reusken, Chantal B.E.M., additional, de Bree, Godelieve J, additional, Sanders, Rogier W., additional, van Gils, Marit, additional, and Heck, Albert J.R., additional

Published
2022
Full Text
View/download PDF

27. Mapping the antigenic diversification of SARS-CoV-2

Author

van der Straten, Karlijn, primary, Guerra, Denise, additional, van Gils, Marit J., additional, Bontjer, Ilja, additional, Caniels, Tom G., additional, van Willigen, Hugo D.G., additional, Wynberg, Elke, additional, Poniman, Meliawati, additional, Burger, Judith A., additional, Bouhuijs, Joey H., additional, van Rijswijk, Jacqueline, additional, Olijhoek, Wouter, additional, Liesdek, Marinus H., additional, Lavell, A. H. Ayesha, additional, Appelman, Brent, additional, Sikkens, Jonne J., additional, Bomers, Marije K., additional, Han, Alvin X., additional, Nichols, Brooke E., additional, Prins, Maria, additional, Vennema, Harry, additional, Reusken, Chantal, additional, de Jong, Menno D., additional, de Bree, Godelieve J., additional, Russell, Colin A., additional, Eggink, Dirk, additional, and Sanders, Rogier W., additional

Published
2022
Full Text
View/download PDF

28. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern

Author

van Gils, Marit J., primary, van Willigen, Hugo D.G., additional, Wynberg, Elke, additional, Han, Alvin X., additional, van der Straten, Karlijn, additional, Burger, Judith A., additional, Poniman, Meliawati, additional, Oomen, Melissa, additional, Tejjani, Khadija, additional, Bouhuijs, Joey H., additional, Verveen, Anouk, additional, Lebbink, Romy, additional, Dijkstra, Maartje, additional, Appelman, Brent, additional, Lavell, A.H. Ayesha, additional, Caniels, Tom G., additional, Bontjer, Ilja, additional, van Vught, Lonneke A., additional, Vlaar, Alexander P.J., additional, Sikkens, Jonne J., additional, Bomers, Marije K., additional, Russell, Colin A., additional, Kootstra, Neeltje A., additional, Sanders, Rogier W., additional, Prins, Maria, additional, de Bree, Godelieve J., additional, de Jong, Menno D., additional, Agard, Ivette, additional, Ayal, Jane, additional, Boyd, Anders, additional, Cavdar, Floor, additional, Craanen, Marianne, additional, Davidovich, Udi, additional, Deuring, Annemarieke, additional, van Dijk, Annelies, additional, Ersan, Ertan, additional, del Grande, Laura, additional, Hartman, Joost, additional, Koedoot, Nelleke, additional, Leenstra, Tjalling, additional, Loomans, Dominique, additional, Makowska, Agata, additional, du Maine, Tom, additional, de Man, Ilja, additional, Matser, Amy, additional, van der Meij, Lizenka, additional, van Polanen, Marleen, additional, Oud, Maria, additional, Reid, Clark, additional, Storey, Leeann, additional, de Wit, Marije, additional, van Wijk, Marc, additional, van Assem, Joyce, additional, van den Aardweg, Joost, additional, van Beek, Marijne, additional, Blankert, Thyra, additional, Boeser-Nunnink, Brigitte, additional, Moll van Charante, Eric, additional, van Dort, Karel, additional, Figaroa, Orlane, additional, Frenkel, Leah, additional, Girigorie, Arginell, additional, van Haga, Jelle, additional, Harskamp-Holwerda, Agnes, additional, Hazenberg, Mette, additional, Hidad, Soemeja, additional, de Jong, Nina, additional, Jonges, Marcel, additional, Jurriaans, Suzanne, additional, Knoop, Hans, additional, Kuijt, Lara, additional, Lok, Anja, additional, Ruiz, Marga Mangas, additional, Maurer, Irma, additional, Nieuwkerk, Pythia, additional, van Nuenen, Ad, additional, van der Veen, Annelou, additional, Verkaik, Bas, additional, and Visser, Gerben-Rienk, additional

Published
2022
Full Text
View/download PDF

29. Recent Infection With HCoV-OC43 Is Associated With Protection Against Sars-Cov-2 Infection

Author

Lavell, A.H. Ayesha, primary, Sikkens, Jonne J., additional, Edridge, Arthur WD, additional, van der Straten, Karlijn, additional, Oomen, Melissa, additional, Buis, David TP, additional, Schinkel, Michiel, additional, Burger, Judith A., additional, Poniman, Meliawati, additional, de Jong, Menno D., additional, de Bree, Godelieve J., additional, Peters, Edgar JG, additional, Smulders, Yvo M., additional, Sanders, Rogier, additional, van Gils, Marit J., additional, van der Hoek, Lia, additional, and Bomers, Marije, additional

Published
2022
Full Text
View/download PDF

30. Immunogenicity of the mRNA-1273 COVID-19 Vaccine in Patients With Inborn Errors of Immunity

Author

van Leeuwen, Leanne, primary, GeurtsvanKessel, Corine, additional, Ellerbroek, Pauline, additional, de Bree, Godelieve J., additional, Potjewijd, Judith, additional, Rutgers, Abraham, additional, Jolink, Hetty, additional, van de Veerdonk, Frank L., additional, van Gorp, Eric, additional, de Wilt, Faye, additional, Bogers, Susanne, additional, Gommers, Lennert, additional, Geers, Daryl, additional, Bruns, Anke, additional, Leavis, Helen, additional, van Haga, Jelle, additional, Lemkes, Bregtje, additional, van Veen, Annelou, additional, de Kruijff, Suzanne, additional, van Paassen, Pieter, additional, de Leeuw, Karina, additional, van der Ven, Annick, additional, Verbeek, Petra, additional, van Wengen, Annelies, additional, Arend, Sandra, additional, Ruten-Budde, Anja, additional, van der Ent, Marianne, additional, van Hagen, Martin, additional, Sanders, Rogier, additional, Grobben, Marloes, additional, van der Straten, Karlijn, additional, Burger, Judith A., additional, Poniman, Meliawati, additional, van Gils, Marit J., additional, de Vries, Rory, additional, and Dalm, Virgil, additional

Published
2022
Full Text
View/download PDF

31. A public antibody class recognizes a novel S2 epitope exposed on open conformations of SARS-CoV-2 spike

Author

Claireaux, Mathieu, primary, Caniels, Tom G, additional, de Gast, Marlon, additional, Han, Julianna, additional, Guerra, Denise, additional, Kerster, Gius, additional, van Schaik, Barbera DC, additional, Jongejan, Aldo, additional, Schriek, Angela I., additional, Grobben, Marloes, additional, Brouwer, Philip JM, additional, van der Straten, Karlijn, additional, Aldon, Yoann, additional, Capella-Pujol, Joan, additional, Snitselaar, Jonne L, additional, Olijhoek, Wouter, additional, Aartse, Aafke, additional, Brinkkemper, Mitch, additional, Bontjer, Ilja, additional, Burger, Judith A, additional, Poniman, Meliawati, additional, Bijl, Tom PL, additional, Torres, Jonathan L, additional, Copps, Jeffrey, additional, Martin, Isabel Cuella, additional, de Taeye, Steven W, additional, de Bree, Godelieve J, additional, Ward, Andrew B, additional, Sliepen, Kwinten, additional, van Kampen, Antoine HC, additional, Moerland, Perry D, additional, Sanders, Rogier W, additional, and van Gils, Marit J, additional

Published
2021
Full Text
View/download PDF

32. Time since SARS-CoV-2 infection and humoral immune response following BNT162b2 mRNA vaccination

Author

Appelman, Brent, primary, van der Straten, Karlijn, additional, Lavell, A.H. Ayesha, additional, Schinkel, Michiel, additional, Slim, Marleen A., additional, Poniman, Meliawati, additional, Burger, Judith A., additional, Oomen, Melissa, additional, Tejjani, Khadija, additional, Vlaar, Alexander P.J., additional, Wiersinga, W. Joost, additional, Smulders, Yvo M., additional, van Vught, Lonneke A., additional, Sanders, Rogier W., additional, van Gils, Marit J., additional, Bomers, Marije K., additional, Sikkens, Jonne J., additional, Appelman, Brent, additional, van de Beek, Diederik, additional, Bomers, Marije K, additional, de Brabander, Justin, additional, Brouwer, Matthijs C, additional, Buis, David TP, additional, Chekrouni, Nora, additional, van Gils, Marit J, additional, de Jong, Menno D, additional, Lavell, AH Ayesha, additional, van Mourik, Niels, additional, Olie, Sabine E, additional, Peters, Edgar JG, additional, Reijnders, Tom DY, additional, Schuurman, Alex R, additional, Sikkens, Jonne J, additional, Slim, Marleen A, additional, Smulders, Yvo M, additional, Vlaar, Alexander PJ, additional, van Vught, Lonneke A, additional, and Wiersinga, W Joost, additional

Published
2021
Full Text
View/download PDF

33. Human milk from previously covid-19-infected mothers: The effect of pasteurization on specific antibodies and neutralization capacity

Author

van Keulen, Britt J, Romijn, Michelle, Bondt, Albert, Dingess, Kelly A, Kontopodi, Eva, van der Straten, Karlijn, den Boer, Maurits A, Burger, Judith A, Poniman, Meliawati, Bosch, Berend J, Brouwer, Philip J M, de Groot, Christianne J M, Hoek, Max, Li, Wentao, Pajkrt, Dasja, Sanders, Rogier W, Schoonderwoerd, Anne, Tamara, Sem, Timmermans, Rian A H, Vidarsson, Gestur, Stittelaar, Koert J, Rispens, Theo T, Hettinga, Kasper A, van Gils, Marit J, Heck, Albert J R, van Goudoever, Johannes B, Sub Biomol.Mass Spectrometry & Proteom., Afd Biomol.Mass Spect. and Proteomics, Virologie, dI&I I&I-1, Biomolecular Mass Spectrometry and Proteomics, Graduate School, Medical Microbiology and Infection Prevention, AII - Infectious diseases, Paediatric Infectious Diseases / Rheumatology / Immunology, ARD - Amsterdam Reproduction and Development, Landsteiner Laboratory, Neonatology, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Pediatric surgery, Obstetrics and gynaecology, Amsterdam Reproduction & Development (AR&D), AGEM - Endocrinology, metabolism and nutrition, ACS - Diabetes & metabolism, Sub Biomol.Mass Spectrometry & Proteom., Afd Biomol.Mass Spect. and Proteomics, Virologie, dI&I I&I-1, and Biomolecular Mass Spectrometry and Proteomics

Subjects
Adult, 0301 basic medicine, Epidemiology, Bioinformatica & Diermodellen, Breastfeeding, Pasteurization, Immunoglobulins, Biology, Antibodies, Viral, medicine.disease_cause, Article, Neutralization, Microbiology, law.invention, 03 medical and health sciences, law, Lactation, Bio-informatics & Animal models, medicine, Humans, TX341-641, Epidemiology, Bio-informatics & Animal models, Coronavirus, VLAG, Epidemiologie, 030109 nutrition & dietetics, Nutrition and Dietetics, Milk, Human, SARS-CoV-2, Nutrition. Foods and food supply, Outbreak, COVID-19, Antibodies, Neutralizing, 030104 developmental biology, medicine.anatomical_structure, Food Quality and Design, Immunization, Epidemiologie, Bioinformatica & Diermodellen, biology.protein, Food Technology, Female, Antibody, Food Science
Abstract

Background: Since the outbreak of coronavirus disease 2019 (COVID-19), many put their hopes in the rapid availability of effective immunizations. Human milk, containing antibodies against syndrome coronavirus 2 (SARS-CoV-2), may serve as means of protection through passive immunization. We aimed to determine the presence and pseudovirus neutralization capacity of SARS-CoV-2 specific IgA in human milk of mothers who recovered from COVID-19, and the effect of pasteurization on these antibodies. Methods: This prospective case control study included lactating mothers, recovered from (suspected) COVID-19 and healthy controls. Human milk and serum samples were collected. To assess the presence of SARS-CoV-2 antibodies we used multiple complementary assays, namely ELISA with the SARS-CoV-2 spike protein (specific for IgA and IgG), receptor binding domain (RBD) and nucleocapsid (N) protein for IgG in serum, and bridging ELISA with the SARS-CoV-2 RBD and N protein for specific Ig (IgG, IgM and IgA in human milk and serum). To assess the effect of pasteurization, human milk was exposed to Holder (HoP) and High Pressure Pasteurization (HPP). Results: Human milk contained abundant SARS-CoV-2 antibodies in 83% of the proven cases and in 67% of the suspected cases. Unpasteurized milk with and without these antibodies was found to be capable of neutralizing a pseudovirus of SARS-CoV-2 in (97% and 85% of the samples respectively). After pasteurization, total IgA antibody levels were affected by HoP, while SARS-CoV-2 specific antibody levels were affected by HPP. Pseudovirus neutralizing capacity of the human milk samples was only retained with the HPP approach. No correlation was observed between milk antibody levels and neutralization capacity. Conclusions: Human milk from recovered COVID-19-infected mothers contains SARS-CoV-2 specific antibodies which maintained neutralization capacity after HPP. All together this may represent a safe and effective immunization strategy after HPP.

Published
2021

34. Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects Macaques from infection

Author

Sulbaran, Guidenn, primary, Maisonnasse, Pauline, additional, Amen, Axelle, additional, Guilligay, Delphine, additional, Dereuddre-Bosquet, Nathalie, additional, Burger, Judith A., additional, Poniman, Meliawati, additional, Buisson, Marlyse, additional, Dergan Dylon, Sebastian, additional, Naninck, Thibaut, additional, Lemaître, Julien, additional, Gros, Wesley, additional, Gallouët, Anne-Sophie, additional, Marlin, Romain, additional, Bouillier, Camille, additional, Contreras, Vanessa, additional, Relouzat, Francis, additional, Fenel, Daphna, additional, Thepaut, Michel, additional, Bally, Isabelle, additional, Thielens, Nicole, additional, Fieschi, Franck, additional, Schoehn, Guy, additional, van der Werf, Sylvie, additional, van Gils, Marit J., additional, Sanders, Rogier W., additional, Poignard, Pascal, additional, Le Grand, Roger, additional, and Weissenhorn, Winfried, additional

Published
2021
Full Text
View/download PDF

35. Cross-reactive antibodies after SARS-CoV-2 infection and vaccination

Author

Grobben, Marloes, primary, van der Straten, Karlijn, additional, Brouwer, Philip J.M., additional, Brinkkemper, Mitch, additional, Maisonnasse, Pauline, additional, Dereuddre-Bosquet, Nathalie, additional, Burger, Judith A., additional, Poniman, Meliawati, additional, Oomen, Melissa, additional, Eggink, Dirk, additional, Bijl, Tom P.L., additional, van Willigen, Hugo D.G., additional, Wynberg, Elke, additional, Verkaik, Bas J., additional, Figaroa, Orlane J.A., additional, de Vries, Peter J., additional, Boertien, Tessel M., additional, Grand, Roger Le, additional, de Jong, Menno D., additional, Prins, Maria, additional, Chung, Amy W., additional, de Bree, Godelieve J., additional, Sanders, Rogier W., additional, and van Gils, Marit J., additional

Published
2021
Full Text
View/download PDF

36. Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike

Author

Derking, Ronald, primary, Allen, Joel D., additional, Cottrell, Christopher A., additional, Sliepen, Kwinten, additional, Seabright, Gemma E., additional, Lee, Wen-Hsin, additional, Aldon, Yoann, additional, Rantalainen, Kimmo, additional, Antanasijevic, Aleksandar, additional, Copps, Jeffrey, additional, Yasmeen, Anila, additional, Cupo, Albert, additional, Cruz Portillo, Victor M., additional, Poniman, Meliawati, additional, Bol, Niki, additional, van der Woude, Patricia, additional, de Taeye, Steven W., additional, van den Kerkhof, Tom L.G.M., additional, Klasse, P.J., additional, Ozorowski, Gabriel, additional, van Gils, Marit J., additional, Moore, John P., additional, Ward, Andrew B., additional, Crispin, Max, additional, and Sanders, Rogier W., additional

Published
2021
Full Text
View/download PDF

37. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection

Author

Brouwer, Philip J.M., primary, Brinkkemper, Mitch, additional, Maisonnasse, Pauline, additional, Dereuddre-Bosquet, Nathalie, additional, Grobben, Marloes, additional, Claireaux, Mathieu, additional, de Gast, Marlon, additional, Marlin, Romain, additional, Chesnais, Virginie, additional, Diry, Ségolène, additional, Allen, Joel D., additional, Watanabe, Yasunori, additional, Giezen, Julia M., additional, Kerster, Gius, additional, Turner, Hannah L., additional, van der Straten, Karlijn, additional, van der Linden, Cynthia A., additional, Aldon, Yoann, additional, Naninck, Thibaut, additional, Bontjer, Ilja, additional, Burger, Judith A., additional, Poniman, Meliawati, additional, Mykytyn, Anna Z., additional, Okba, Nisreen M.A., additional, Schermer, Edith E., additional, van Breemen, Marielle J., additional, Ravichandran, Rashmi, additional, Caniels, Tom G., additional, van Schooten, Jelle, additional, Kahlaoui, Nidhal, additional, Contreras, Vanessa, additional, Lemaître, Julien, additional, Chapon, Catherine, additional, Fang, Raphaël Ho Tsong, additional, Villaudy, Julien, additional, Sliepen, Kwinten, additional, van der Velden, Yme U., additional, Haagmans, Bart L., additional, de Bree, Godelieve J., additional, Ginoux, Eric, additional, Ward, Andrew B., additional, Crispin, Max, additional, King, Neil P., additional, van der Werf, Sylvie, additional, van Gils, Marit J., additional, Le Grand, Roger, additional, and Sanders, Rogier W., additional

Published
2021
Full Text
View/download PDF

38. COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models

Author

Maisonnasse, Pauline, primary, Aldon, Yoann, additional, Marc, Aurélien, additional, Marlin, Romain, additional, Dereuddre-Bosquet, Nathalie, additional, Kuzmina, Natalia, additional, Freyn, Alec, additional, Snitselaar, Jonne, additional, Gonçalves, Antonio, additional, Caniels, Tom, additional, Burger, Judith, additional, Poniman, Meliawati, additional, Chesnais, Virginie, additional, Diry, Ségolène, additional, Iershov, Anton, additional, Ronk, Adam, additional, Jangra, Sonia, additional, Rathnasinghe, Raveen, additional, Brouwer, Philip, additional, Bijl, Tom, additional, Schooten, Jelle van, additional, Brinkkemper, Mitch, additional, Liu, Hejun, additional, Yuan, Meng, additional, Mire, Chad, additional, Breemen, Mariëlle van, additional, Contreras, Vanessa, additional, Naninck, Thibaut, additional, Lemaitre, Julien, additional, Kahlaoui, Nidhal, additional, Relouzat, Francis, additional, Chapon, Catherine, additional, Fang, Raphael Ho Tsong, additional, McDanal, Charlene, additional, Osei-Twum, Mary, additional, St-Amant, Natalie, additional, Gagnon, Luc, additional, Montefiori, David, additional, Wilson, Ian, additional, Ginoux, Eric, additional, de Bree, Godelieve, additional, Garcia-Sastre, Adolfo, additional, Schotsaert, Michael, additional, Coughlan, Lynda, additional, Bukreyev, Alexander, additional, Werf, Sylvie van der, additional, Guedj, Jeremie, additional, Sanders, Rogier, additional, Gils, Marit van, additional, and Grand, Roger Le, additional

Published
2021
Full Text
View/download PDF

39. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection

Author

Brouwer, Philip J. M., primary, Brinkkemper, Mitch, additional, Maisonnasse, Pauline, additional, Dereuddre-Bosquet, Nathalie, additional, Grobben, Marloes, additional, Claireaux, Mathieu, additional, de Gast, Marlon, additional, Marlin, Romain, additional, Chesnais, Virginie, additional, Diry, Ségolène, additional, Allen, Joel D., additional, Watanabe, Yasunori, additional, Giezen, Julia M., additional, Kerster, Gius, additional, Turner, Hannah L., additional, van der Straten, Karlijn, additional, van der Linden, Cynthia A., additional, Aldon, Yoann, additional, Naninck, Thibaut, additional, Bontjer, Ilja, additional, Burger, Judith A., additional, Poniman, Meliawati, additional, Mykytyn, Anna Z., additional, Okba, Nisreen M. A., additional, Schermer, Edith E., additional, van Breemen, Marielle J., additional, Ravichandran, Rashmi, additional, Caniels, Tom G., additional, van Schooten, Jelle, additional, Kahlaoui, Nidhal, additional, Contreras, Vanessa, additional, Lemaître, Julien, additional, Chapon, Catherine, additional, Ho Tsong Fang, Raphaël, additional, Villaudy, Julien, additional, Sliepen, Kwinten, additional, van der Velden, Yme U., additional, Haagmans, Bart L., additional, de Bree, Godelieve J., additional, Ginoux, Eric, additional, Ward, Andrew B., additional, Crispin, Max, additional, King, Neil P., additional, van der Werf, Sylvie, additional, van Gils, Marit J., additional, Grand, Roger Le, additional, and Sanders, Rogier W., additional

Published
2020
Full Text
View/download PDF

40. Cross-reactive antibodies after SARS-CoV-2 infection and vaccination.

Author

Grobben, Marloes, van der Straten, Karlijn, Brouwer, Philip J. M., Brinkkemper, Mitch, Maisonnasse, Pauline, Dereuddre-Bosquet, Nathalie, Appelman, Brent, Lavell, A. H. Ayesha, van Vught, Lonneke A., Burger, Judith A., Poniman, Meliawati, Oomen, Melissa, Eggink, Dirk, Bijl, Tom P. L., van Willigen, Hugo D. G., Wynberg, Elke, Verkaik, Bas J., Figaroa, Orlane J. A., de Vries, Peter J., and Boertien, Tessel M.

Published
2021
Full Text
View/download PDF

41. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern

Author

van Gils, Marit J., van Willigen, Hugo D.G., Wynberg, Elke, Han, Alvin X., van der Straten, Karlijn, Burger, Judith A., Poniman, Meliawati, Oomen, Melissa, Tejjani, Khadija, Bouhuijs, Joey H., Verveen, Anouk, Lebbink, Romy, Dijkstra, Maartje, Appelman, Brent, Lavell, A.H. Ayesha, Caniels, Tom G., Bontjer, Ilja, van Vught, Lonneke A., Vlaar, Alexander P.J., Sikkens, Jonne J., Bomers, Marije K., Russell, Colin A., Kootstra, Neeltje A., Sanders, Rogier W., Prins, Maria, de Bree, Godelieve J., and de Jong, Menno D.

Abstract

The urgent need for, but limited availability of, SARS-CoV-2 vaccines worldwide has led to widespread consideration of dose-sparing strategies. Here, we evaluate the SARS-CoV-2-specific antibody responses following BNT162b2 vaccination in 150 previously SARS-CoV-2-infected individuals from a population-based cohort. One week after first vaccine dose, spike protein antibody levels are 27-fold higher and neutralizing antibody titers 12-fold higher, exceeding titers of fully vaccinated SARS-CoV-2-naive controls, with minimal additional boosting after the second dose. Neutralizing antibody titers against four variants of concern increase after vaccination; however, overall neutralization breadth does not improve. Pre-vaccination neutralizing antibody titers and time since infection have the largest positive effect on titers following vaccination. COVID-19 severity and the presence of comorbidities have no discernible impact on vaccine response. In conclusion, a single dose of BNT162b2 vaccine up to 15 months after SARS-CoV-2 infection offers higher neutralizing antibody titers than 2 vaccine doses in SARS-CoV-2-naive individuals.

Published
2021
Full Text
View/download PDF

42. Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination.

Author

Caniels, Tom G., Bontjer, Ilja, van der Straten, Karlijn, Poniman, Meliawati, Burger, Judith A., Appelman, Brent, Lavell, H. A. Ayesha, Oomen, Melissa, Godeke, Gert-Jan, Valle, Coralie, Mögling, Ramona, van Willigen, Hugo D. G., Wynberg, Elke, Schinkel, Michiel, van Vught, Lonneke A., Guerra, Denise, Snitselaar, Jonne L., Chaturbhuj, Devidas N., Martin, Isabel Cuella, and Moore, John P.

Subjects
*SARS-CoV-2, *COVID-19, *HUMORAL immunity, *MEDICAL personnel, *REVERSE transcriptase polymerase chain reaction
Published
2021
Full Text
View/download PDF

43. Broadening sarbecovirus neutralization with bispecific antibodies combining distinct conserved targets on the receptor binding domain.

Author

Guerra D, Radić L, Brinkkemper M, Poniman M, van der Maas L, Torres JL, Ward AB, Sliepen K, Schinkel J, Sanders RW, van Gils MJ, and Beaumont T

Subjects
Humans, COVID-19 immunology, COVID-19 prevention & control, Epitopes immunology, Neutralization Tests, Animals, Antibodies, Monoclonal immunology, Antibodies, Bispecific immunology, SARS-CoV-2 immunology, Antibodies, Viral immunology, Antibodies, Neutralizing immunology, Spike Glycoprotein, Coronavirus immunology
Abstract

Monoclonal neutralizing antibodies (mAbs) are considered an important prophylactic against SARS-CoV-2 infection in at-risk populations and a strategy to counteract future sarbecovirus-induced disease. However, most mAbs isolated so far neutralize only a few sarbecovirus strains. Therefore, there is a growing interest in bispecific antibodies (bsAbs) which can simultaneously target different spike epitopes and thereby increase neutralizing breadth and prevent viral escape. Here, we generate and characterize a panel of 30 novel broadly reactive bsAbs using an efficient controlled Fab-arm exchange protocol. We specifically combine some of the broadest mAbs described so far, which target conserved epitopes on the receptor binding domain (RBD). Several bsAbs show superior cross-binding and neutralization compared to the parental mAbs and cocktails against sarbecoviruses from diverse clades, including recent SARS-CoV-2 variants. BsAbs which include mAb COVA2-02 are among the most potent and broad combinations. As a result, we study the unknown epitope of COVA2-02 and show that this mAb targets a distinct conserved region at the base of the RBD, which could be of interest when designing next-generation bsAb constructs to contribute to a better pandemic preparedness.

Published
2024
Full Text
View/download PDF

44. Broad SARS-CoV-2 Neutralization by Monoclonal and Bispecific Antibodies Derived from a Gamma-infected Individual.

Author

Guerra D, Beaumont T, RadiÄ L, Kerster G, van der Straten K, Yuan M, Torres JL, Lee WH, Liu H, Poniman M, Bontjer I, Burger JA, Claireaux M, Caniels TG, Snitselaar JL, Bijl TPL, Kruijer S, Ozorowski G, Gideonse D, Sliepen K, Ward AB, Eggink D, de Bree GJ, Wilson IA, Sanders RW, and van Gils MJ

Abstract

The worldwide pandemic caused by SARS-CoV-2 has remained a human medical threat due to the continued evolution of multiple variants that acquire resistance to vaccines and prior infection. Therefore, it is imperative to discover monoclonal antibodies (mAbs) that neutralize a broad range of SARS-CoV-2 variants for therapeutic and prophylactic use. A stabilized autologous SARS-CoV-2 spike glycoprotein was used to enrich antigen-specific B cells from an individual with a primary Gamma variant infection. Five mAbs selected from those B cells showed considerable neutralizing potency against multiple variants of concern, with COVA309-35 being the most potent against the autologous virus, as well as against Omicron BA.1 and BA.2. When combining the COVA309 mAbs as cocktails or bispecific antibody formats, the breadth and potency was significantly improved against all tested variants. In addition, the mechanism of cross-neutralization of the COVA309 mAbs was elucidated by structural analysis. Altogether these data indicate that a Gamma-infected individual can develop broadly neutralizing antibodies.

Published
2022
Full Text
View/download PDF

45. Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination.

Author

Caniels TG, Bontjer I, van der Straten K, Poniman M, Burger JA, Appelman B, Lavell AHA, Oomen M, Godeke GJ, Valle C, Mögling R, van Willigen HDG, Wynberg E, Schinkel M, van Vught LA, Guerra D, Snitselaar JL, Chaturbhuj DN, Martin IC, Moore JP, de Jong MD, Reusken C, Sikkens JJ, Bomers MK, de Bree GJ, van Gils MJ, Eggink D, and Sanders RW

Abstract

Emerging SARS-CoV-2 variants pose a threat to human immunity induced by natural infection and vaccination. We assessed the recognition of three variants of concern (B.1.1.7, B.1.351 and P.1) in cohorts of COVID-19 patients ranging in disease severity (n = 69) and recipients of the Pfizer/BioNTech vaccine (n = 50). Spike binding and neutralization against all three VOC was substantially reduced in the majority of samples, with the largest 4-7-fold reduction in neutralization being observed against B.1.351. While hospitalized COVID-19 patients and vaccinees maintained sufficient neutralizing titers against all three VOC, 39% of non-hospitalized patients did not neutralize B.1.351. Moreover, monoclonal neutralizing antibodies (NAbs) show sharp reductions in their binding kinetics and neutralizing potential to B.1.351 and P.1, but not to B.1.1.7. These data have implications for the degree to which pre-existing immunity can protect against subsequent infection with VOC and informs policy makers of susceptibility to globally circulating SARS-CoV-2 VOC.

Published
2021
Full Text
View/download PDF

46. Human Milk from Previously COVID-19-Infected Mothers: The Effect of Pasteurization on Specific Antibodies and Neutralization Capacity.

Author

van Keulen BJ, Romijn M, Bondt A, Dingess KA, Kontopodi E, van der Straten K, den Boer MA, Burger JA, Poniman M, Bosch BJ, Brouwer PJM, de Groot CJM, Hoek M, Li W, Pajkrt D, Sanders RW, Schoonderwoerd A, Tamara S, Timmermans RAH, Vidarsson G, Stittelaar KJ, Rispens TT, Hettinga KA, van Gils MJ, Heck AJR, and van Goudoever JB

Subjects
Adult, Female, Humans, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, COVID-19 immunology, Lactation, Milk, Human immunology, Pasteurization, SARS-CoV-2 immunology
Abstract

Background: Since the outbreak of coronavirus disease 2019 (COVID-19), many put their hopes in the rapid availability of effective immunizations. Human milk, containing antibodies against syndrome coronavirus 2 (SARS-CoV-2), may serve as means of protection through passive immunization. We aimed to determine the presence and pseudovirus neutralization capacity of SARS-CoV-2 specific IgA in human milk of mothers who recovered from COVID-19, and the effect of pasteurization on these antibodies., Methods: This prospective case control study included lactating mothers, recovered from (suspected) COVID-19 and healthy controls. Human milk and serum samples were collected. To assess the presence of SARS-CoV-2 antibodies we used multiple complementary assays, namely ELISA with the SARS-CoV-2 spike protein (specific for IgA and IgG), receptor binding domain (RBD) and nucleocapsid (N) protein for IgG in serum, and bridging ELISA with the SARS-CoV-2 RBD and N protein for specific Ig (IgG, IgM and IgA in human milk and serum). To assess the effect of pasteurization, human milk was exposed to Holder (HoP) and High Pressure Pasteurization (HPP)., Results: Human milk contained abundant SARS-CoV-2 antibodies in 83% of the proven cases and in 67% of the suspected cases. Unpasteurized milk with and without these antibodies was found to be capable of neutralizing a pseudovirus of SARS-CoV-2 in (97% and 85% of the samples respectively). After pasteurization, total IgA antibody levels were affected by HoP, while SARS-CoV-2 specific antibody levels were affected by HPP. Pseudovirus neutralizing capacity of the human milk samples was only retained with the HPP approach. No correlation was observed between milk antibody levels and neutralization capacity., Conclusions: Human milk from recovered COVID-19-infected mothers contains SARS-CoV-2 specific antibodies which maintained neutralization capacity after HPP. All together this may represent a safe and effective immunization strategy after HPP.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results